Aravive (NASDAQ: ARAV) on Thursday said Gail McIntyre, the company’s chief scientific officer, has been promoted to CEO. McIntyre, who joined the company since 2016, succeeds Rekha Hemrajani, who has resigned, along with three board directors.
The company called the leadership transition a “natural evolution” following its company’s reverse merger in June 2018 with Versartis, a Menlo Park, CA-based company whose lead drug failed a clinical trial the year prior. Houston-based Aravive is developing treatments for diseases including cancer and fibrosis.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
